VYNE Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VYNE Therapeutics Inc.
In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
Cara Therapeutics and licensee Vifor Pharma have released positive topline data from the KALM-2 study in chronic kidney disease patients with moderate-to-severe pruritus undergoing hemodialysis, using a first-in-class selective kappa opioid receptor agonist which does not enter the CNS.
With Foamix merger closing soon, Menlo’s serlopitant failed a Phase II trial in chronic pruritus of unknown origin, but the firm said a Phase III program in prurigo nodularis shouldn’t be affected. Its share in the new company is contingent on the PN data.
- Other Names / Subsidiaries
- Foamix Pharmaceuticals Ltd.
- Tigercat Pharma, Inc.
- Menlo Therapeutics, Inc.